The mitochondrial permeability transition pore and cancer: Molecular mechanisms involved in cell death

Frontiers in Oncology

Volumn 4, Issue NOV, 2014, Pages

  Bonora, Massimo ^a   Pinton, Paolo ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

Apoptosis; ATP synthase; Cancer; Necrosis; Permeability transition pore; PTP; ROS; Tumors

Indexed keywords

MITOCHONDRIAL PERMEABILITY TRANSITION PORE;

APOPTOSIS; CANCER GROWTH; CELL DEATH; GENE OVEREXPRESSION; HUMAN; MISSENSE MUTATION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; STRUCTURAL GENE;

EID: 84915815164     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00302     Document Type: Review

References (148)

1. Hunter DR, Haworth RA. The Ca2+-induced membrane transition in mitochondria. I. The protective mechanisms. Arch Biochem Biophys (1979) 195:453-9. doi: 10.1016/0003-9861(79)90371-0
2. Crompton M, Costi A. A heart mitochondrial Ca2(+)-dependent pore of possible relevance to re-perfusion-induced injury. Evidence that ADP facilitates pore interconversion between the closed and open states. Biochem J (1990) 266:33-9.
3. Takeyama N, Matsuo N, Tanaka T. Oxidative damage to mitochondria is mediated by the Ca(2+)-dependent inner-membrane permeability transition. Biochem J (1993) 294(Pt 3):719-25.
4. Javadov S, Karmazyn M. Cellular physiology biochemistry and biochemistry mitochondrial permeability transition pore opening as an endpoint to initiate cell death and as a putative target for cardioprotection. Cell Physiol Biochem (2007) 1:1-22. doi:10.1159/000103747
5. Hausenloy DJ, Boston-Griffiths EA, Yellon DM. Cyclosporin A and cardioprotection: from investigative tool to therapeutic agent. Br J Pharmacol (2012) 165:1235-45. doi:10.1111/j.1476-5381.2011.01700.x
6. Osman MM, Lulic D, Glover L, Stahl CE, Lau T, van Loveren H, et al. Cyclosporine-A as a neuroprotective agent against stroke: its translation from laboratory research to clinical application. Neuropeptides (2011) 45:359-68. doi:10.1016/j.npep.2011.04.002
7. Basso E, Fante L, Fowlkes J, Petronilli V, Forte MA, Bernardi P. Properties of the permeability transition pore in mitochondria devoid of cyclophilin D. J Biol Chem (2005) 280:18558-61. doi:10.1074/jbc. C500089200
8. Schinzel AC, Takeuchi O, Huang Z, Fisher JK, Zhou Z, Rubens J, et al. Cyclophilin D is a component of mitochondrial permeability transition and mediates neuronal cell death after focal cerebral ischemia. Proc Natl Acad Sci U S A (2005) 102:12005-10. doi:10.1073/pnas.0505294102
9. Kantrow SP, Piantadosi CA. Release of cytochrome c from liver mitochondria during permeability transition. Biochem Biophys Res Commun (1997) 232:669-71. doi:10.1006/bbrc.1997.6353
10. Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, Brothers GM, et al. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature (1999) 397:441-6. doi:10.1038/17135
11. Zhou LL, Zhou LY, Luo KQ, Chang DC. Smac/DIABLO and cytochrome c are released from mitochondria through a similar mechanism during UV-induced apoptosis. Apoptosis (2005) 10:289-99. doi:10.1007/s10495-005-0803-9
12. Davies AM, Hershman S, Stabley GJ, Hoek JB, Peterson J, Cahill A. A Ca2+-induced mitochondrial permeability transition causes complete release of rat liver endonuclease G activity from its exclusive location within the mitochondrial intermembrane space. Identification of a novel endo-exonuclease activity residing within. Nucleic Acids Res (2003) 31:1364-73. doi:10.1093/nar/gkg205
13. Ellerby HM, Martin SJ, Ellerby LM, Naiem SS, Rabizadeh S, Salvesen GS, et al. Establishment of a cell-free system of neuronal apoptosis: comparison of premitochondrial, mitochondrial, and postmitochondrial phases. J Neurosci (1997) 17:6165-78.
14. Marchetti P, Castedo M, Susin SA, Zamzami N, Hirsch T, Macho A, et al. Mitochondrial permeability transition is a central coordinating event of apoptosis. J Exp Med (1996) 184:1155-60. doi:10.1084/jem.184.3.1155
15. Narita M, Shimizu S, Ito T, Chittenden T, Lutz RJ, Matsuda H, et al. Bax interacts with the permeability transition pore to induce permeability transition and cytochrome c release in isolated mitochondria. Proc Natl Acad Sci (1998) 95:14681-6. doi:10.1073/pnas.95.25.14681
16. Marzo I, Brenner C, Zamzami N, Jürgensmeier JM, Susin SA, Vieira HL, et al. Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis. Science (1998) 281:2027-31. doi:10.1126/science.281.5385.2027
17. Bonora M, Patergnani S, Rimessi A, De Marchi E, Suski JM, Bononi A, et al. ATP synthesis and storage. Purinergic Signal (2012) 8:343-57. doi:10.1007/s11302-012-9305-8
18. Duchen MR, Leyssens A, Crompton M. Transient mitochondrial depolarizations reflect focal sarcoplasmic reticular calcium release in single rat cardiomyocytes. J Cell Biol (1998) 142:975-88. doi:10.1083/jcb.142.4.975
19. Zhao H, Yenari MA, Cheng D, Sapolsky RM, Steinberg GK. Biphasic cytochrome c release after transient global ischemia and its inhibition by hypothermia. J Cereb Blood Flow Metab (2005) 25:1119-29. doi:10.1038/sj.jcbfm.9600111
20. Ott M, Robertson JD, Gogvadze V, Zhivotovsky B, Orrenius S. Cytochrome c release from mitochondria proceeds by a two-step process. Proc Natl Acad Sci U S A (2002) 99:1259-63. doi:10.1073/pnas.241655498
21. Zamaraeva MV, Sabirov RZ, Manabe K, Okada Y. Ca(2+)-dependent glycolysis activation mediates apoptotic ATP elevation in HeLa cells. Biochem Biophys Res Commun (2007) 363:687-93. doi:10.1016/j.bbrc.2007.09.019
22. Baines CP, Kaiser RA, Purcell NH, Blair NS, Osinska H, Hambleton MA, et al. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature (2005) 434:658-62. doi:10.1038/nature03434
23. Zhang Q, Huang W-D, Lv X-Y, Yang Y-M. Ghrelin protects H9c2 cells from hydrogen peroxide-induced apoptosis through NF-κB and mitochondria-mediated signaling. Eur J Pharmacol (2011) 654:142-9. doi:10.1016/j.ejphar.2010.12.011
24. Gechev TS, Hille J. Hydrogen peroxide as a signal controlling plant programmed cell death. J Cell Biol (2005) 168:17-20. doi:10.1083/jcb.200409170
25. Zhang Z, Zheng L, Zhao Z, Shi J, Wang X, Huang J. Grape seed proanthocyanidins inhibit H2O2-induced osteoblastic MC3T3-E1 cell apoptosis via ameliorating H2O2-induced mitochondrial dysfunction. J Toxicol Sci (2014) 39:803-13. doi:10.2131/jts.39.803
26. Li R, Yan G, Li Q, Sun H, Hu Y, Sun J, et al. MicroRNA-145 protects cardiomyocytes against hydrogen peroxide (H2O2)-induced apoptosis through targeting the mitochondria apoptotic pathway. PLoS One (2012) 7:e44907. doi:10.1371/journal.pone.0044907
27. Marchi S, Patergnani S, Pinton P. The endoplasmic reticulum-mitochondria connection: one touch, multiple functions. Biochim Biophys Acta (2014) 1837:461-9. doi:10.1016/j.bbabio.2013.10.015
28. Patergnani S, Suski JM, Agnoletto C, Bononi A, Bonora M, De Marchi E, et al. Calcium signaling around mitochondria associated membranes (MAMs). Cell Commun Signal (2011) 9:19. doi:10.1186/1478-811X-9-19
29. Giorgi C, Romagnoli A, Pinton P, Rizzuto R. Ca2+ signaling, mitochondria and cell death. Curr Mol Med (2008) 8:119-30. doi:10.2174/156652408783769571
30. Giorgi C, Baldassari F, Bononi A, Bonora M, De Marchi E, Marchi S, et al. Mitochondrial Ca(2+) and apoptosis. Cell Calcium (2012) 52:36-43. doi:10.1016/j.ceca.2012.02.008
31. Marchi S, Lupini L, Patergnani S, Rimessi A, Missiroli S, Bonora M, et al. Downregulation of the mitochondrial calcium uniporter by cancer-related miR-25. Curr Biol (2013) 23:58-63. doi:10.1016/j.cub.2012.11.026
32. Shoshan-Barmatz V, Mizrachi D. VDAC1: from structure to cancer therapy. Front Oncol (2012) 2:164. doi:10.3389/fonc.2012.00164
33. Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev (2007) 87:99-163. doi:10.1152/physrev.00013.2006
34. Karch J, Kwong JQ, Burr AR, Sargent MA, Elrod JW, Peixoto PM, et al. Bax and Bak function as the outer membrane component of the mitochondrial permeability pore in regulating necrotic cell death in mice. Elife (2013) 2:e00772. doi:10.7554/eLife.00772
35. Scorrano L, Oakes SA, Opferman JT, Cheng EH, Sorcinelli MD, Pozzan T, et al. BAX and BAK regulation of endoplasmic reticulum Ca2+: a control point for apoptosis. Science (2003) 300:135-9. doi:10.1126/science.1081208
36. Schroers A, Krämer R, Wohlrab H. The reversible antiport-uniport conversion of the phosphate carrier from yeast mitochondria depends on the presence of a single cysteine. J Biol Chem (1997) 272:10558-64. doi:10.1074/jbc.272.16.10558
37. Leung AWC, Varanyuwatana P, Halestrap AP. The mitochondrial phosphate carrier interacts with cyclophilin D and may play a key role in the permeability transition. J Biol Chem (2008) 283:26312-23. doi:10.1074/jbc. M805235200
38. Alcalá S, Klee M, Fernández J, Fleischer A, Pimentel-Muiños FX. A high-throughput screening for mammalian cell death effectors identifies the mitochondrial phosphate carrier as a regulator of cytochrome c release. Oncogene (2008) 27:44-54. doi:10.1038/sj.onc.1210600
39. Varanyuwatana P, Halestrap AP. The roles of phosphate and the phosphate carrier in the mitochondrial permeability transition pore. Mitochondrion (2012) 12:120-5. doi:10.1016/j.mito.2011.04.006
40. Gutiérrez-Aguilar M, Douglas DL, Gibson AK, Domeier TL, Molkentin JD, Baines CP. Genetic manipulation of the cardiac mitochondrial phosphate carrier does not affect permeability transition. J Mol Cell Cardiol (2014) 72:316-25. doi:10.1016/j.yjmcc.2014.04.008
41. Kwong JQ, Davis J, Baines CP, Sargent MA, Karch J, Wang X, et al. Genetic deletion of the mitochondrial phosphate carrier desensitizes the mitochondrial permeability transition pore and causes cardiomyopathy. Cell Death Differ (2014) 21:1209-17. doi:10.1038/cdd.2014.36
42. Li B, Chauvin C, De Paulis D, De Oliveira F, Gharib A, Vial G, et al. Inhibition of complex I regulates the mitochondrial permeability transition through a phosphate-sensitive inhibitory site masked by cyclophilin D. Biochim Biophys Acta (2012) 1817:1628-34. doi:10.1016/j.bbabio.2012.05.011
43. Fontaine E, Eriksson O, Ichas F, Bernardi P. Regulation of the permeability transition pore in skeletal muscle mitochondria. Modulation by electron flow through the respiratory chain complex i. J Biol Chem (1998) 273:12662-8. doi:10.1074/jbc.273.20.12662
44. Batandier C, Leverve X, Fontaine E. Opening of the mitochondrial permeability transition pore induces reactive oxygen species production at the level of the respiratory chain complex I. J Biol Chem (2004) 279:17197-204. doi:10.1074/jbc. M310329200
45. Chinopoulos C, Konràd C, Kiss G, Metelkin E, Töröcsik B, Zhang SF, et al. Modulation of F0F1-ATP synthase activity by cyclophilin D regulates matrix adenine nucleotide levels. FEBS J (2011) 278:1112-25. doi:10.1111/j.1742-4658.2011.08026.x
46. Bonora M, Wieckowski MR, Chinopoulos C, Kepp O, Kroemer G, Galluzzi L, et al. Molecular mechanisms of cell death: central implication of ATP synthase in mitochondrial permeability transition. Oncogene (2014). doi:10.1038/onc.2014.96
47. Morciano G, Giorgi C, Bonora M, Punzetti S, Pavasini R, Wieckowski MR, et al. Molecular identity of the mitochondrial permeability transition pore and its role in ischemia-reperfusion injury. J Mol Cell Cardiol (2014). doi:10.1016/j.yjmcc.2014.08.015
48. Giorgio V, von Stockum S, Antoniel M, Fabbro A, Fogolari F, Forte M, et al. Dimers of mitochondrial ATP synthase form the permeability transition pore. Proc Natl Acad Sci U S A (2013) 110:5887-92. doi:10.1073/pnas.1217823110
49. Giorgio V, Bisetto E, Soriano ME, Dabbeni-Sala F, Basso E, Petronilli V, et al. Cyclophilin D modulates mitochondrial F0F1-ATP synthase by interacting with the lateral stalk of the complex. J Biol Chem (2009) 284:33982-8. doi:10.1074/jbc. M109.020115
50. Bonora M, Bononi A, De Marchi E, Giorgi C, Lebiedzinska M, Marchi S, et al. Role of the c subunit of the FO ATP synthase in mitochondrial permeability transition. Cell Cycle (2013) 12:674-83. doi:10.4161/cc.23599
51. De Marchi E, Bonora M, Giorgi C, Pinton P. The mitochondrial permeability transition pore is a dispensable element for mitochondrial calcium efflux. Cell Calcium (2014) 56:1-13. doi:10.1016/j.ceca.2014.03.004
52. Azarashvili T, Odinokova I, Bakunts A, Ternovsky V, Krestinina O, Tyynelä J, et al. Potential role of subunit c of F0F1-ATPase and subunit c of storage body in the mitochondrial permeability transition. Effect of the phosphorylation status of subunit c on pore opening. Cell Calcium (2014) 55:69-77. doi:10.1016/j.ceca.2013.12.002
53. Alavian KN, Beutner G, Lazrove E, Sacchetti S, Park H-A, Licznerski P, et al. An uncoupling channel within the c-subunit ring of the F1FO ATP synthase is the mitochondrial permeability transition pore. Proc Natl Acad Sci U S A (2014) 111(29):10580-5. doi:10.1073/pnas.1401591111
54. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell (2011) 144:646-74. doi:10.1016/j.cell.2011.02.013
55. Zhang D, Lu C, Whiteman M, Chance B, Armstrong JS. The mitochondrial permeability transition regulates cytochrome c release for apoptosis during endoplasmic reticulum stress by remodeling the cristae junction. J Biol Chem (2008) 283:3476-86. doi:10.1074/jbc. M707528200
56. Zunino SJ, Storms DH. Resveratrol-induced apoptosis is enhanced in acute lymphoblastic leukemia cells by modulation of the mitochondrial permeability transition pore. Cancer Lett (2006) 240:123-34. doi:10.1016/j.canlet.2005.09.001
57. Pinton P, Ferrari D, Rapizzi E, Di Virgilio F, Pozzan T, Rizzuto R. The Ca2+ concentration of the endoplasmic reticulum is a key determinant of ceramide-induced apoptosis: significance for the molecular mechanism of Bcl-2 action. EMBO J (2001) 20:2690-701. doi:10.1093/emboj/20.11.2690
58. Baumgartner HK, Gerasimenko JV, Thorne C, Ferdek P, Pozzan T, Tepikin AV, et al. Calcium elevation in mitochondria is the main Ca2+ requirement for mitochondrial permeability transition pore (mPTP) opening. J Biol Chem (2009) 284:20796-803. doi:10.1074/jbc. M109.025353
59. Giorgi C, De Stefani D, Bononi A, Rizzuto R, Pinton P. Structural and functional link between the mitochondrial network and the endoplasmic reticulum. Int J Biochem Cell Biol (2009) 41:1817-27. doi:10.1016/j.biocel.2009.04.010
60. Bernardi R, PandolfiPP. A dialog on the first 20 years of PML research and the next 20 ahead. Front Oncol (2014) 4:23. doi:10.3389/fonc.2014.00023
61. Pulido R, Baker SJ, Barata JT, Carracedo A, Cid VJ, Chin-Sang ID, et al. A unified nomenclature and amino acid numbering for human PTEN. Sci Signal (2014) 7:e15. doi:10.1126/scisignal.2005560
62. Marchi S, Pinton P. The mitochondrial calcium uniporter complex: molecular components, structure and physiopathological implications. J Physiol (2014) 592:829-39. doi:10.1113/jphysiol.2013.268235
63. Giorgi C, Ito K, Lin H, Santangelo C, Wieckowski MR, Lebiedzinska M, et al. PML regulates apoptosis at endoplasmic reticulum by modulating calcium release. Science (2010) 330:1247-51. doi:10.1126/science.1189157
64. Bononi A, Bonora M, Marchi S, Missiroli S, Poletti F, Giorgi C, et al. Identification of PTEN at the ER and MAMs and its regulation of Ca(2+) signaling and apoptosis in a protein phosphatase-dependent manner. Cell Death Differ (2013) 20:1631-43. doi:10.1038/cdd.2013.77
65. Pinton P, Ferrari D, Magalhães P, Schulze-OsthoffK, Di Virgilio F, Pozzan T, et al. Reduced loading of intracellular Ca(2+) stores and downregulation of capacitative Ca(2+) influx in Bcl-2-overexpressing cells. J Cell Biol (2000) 148:857-62. doi:10.1083/jcb.148.5.857
66. Kang J, Pervaiz S. Crosstalk between Bcl-2 family and Ras family small GTPases: potential cell fate regulation? Front Oncol (2012) 2:206. doi:10.3389/fonc.2012.00206
67. Rimessi A, Marchi S, Patergnani S, Pinton P. H-Ras-driven tumoral maintenance is sustained through caveolin-1-dependent alterations in calcium signaling. Oncogene (2014) 33(18):2329-40. doi:10.1038/onc.2013.192
68. Gupta SC, Hevia D, Patchva S, Park B, Koh W, Aggarwal BB. Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy. Antioxid Redox Signal (2012) 16:1295-322. doi:10.1089/ars.2011.4414
69. Yang Y, Karakhanova S, Werner J, Bazhin AV. Reactive oxygen species in cancer biology and anticancer therapy. Curr Med Chem (2013) 20:3677-92. doi:10.2174/0929867311320999165
70. Dvorakova K, Payne CM, Tome ME, Briehl MM, Vasquez MA, Waltmire CN, et al. Molecular and cellular characterization of imexon-resistant RPMI8226/I myeloma cells. Mol Cancer Ther (2002) 1:185-95. Available from: http://mct.aacrjournals.org/content/1/3/185.long
71. Biaglow JE, Miller RA. The thioredoxin reductase/thioredoxin system: novel redox targets for cancer therapy. Cancer Biol Ther (2005) 4:6-13. doi:10.4161/cbt.4.1.1434
72. Pani G, Colavitti R, Bedogni B, Fusco S, Ferraro D, Borrello S, et al. Mitochondrial superoxide dismutase: a promising target for new anticancer therapies. Curr Med Chem (2004) 11:1299-308. doi:10.2174/0929867043365297
73. Brenner C, Grimm S. The permeability transition pore complex in cancer cell death. Oncogene (2006) 25:4744-56. doi:10.1038/sj.onc.1209609
74. Fulda S, Galluzzi L, Kroemer G. Targeting mitochondria for cancer therapy. Nat Rev Drug Discov (2010) 9:447-64. doi:10.1038/nrd3137
75. Shinohara Y, Ishida T, Hino M, Yamazaki N, Baba Y, Terada H. Characterization of porin isoforms expressed in tumor cells. Eur J Biochem (2000) 267:6067-73. doi:10.1046/j.1432-1327.2000.01687.x
76. Beinlich A, Strohmeier R, Kaufmann M, Kuhl H. Relation of cell proliferation to expression of peripheral benzodiazepine receptors in human breast cancer cell lines. Biochem Pharmacol (2000) 60:397-402. doi:10.1016/S0006-2952(00)00325-7
77. Maaser K, Höpfner M, Jansen A, Weisinger G, Gavish M, Kozikowski AP, et al. Specific ligands of the peripheral benzodiazepine receptor induce apoptosis and cell cycle arrest in human colorectal cancer cells. Br J Cancer (2001) 85:1771-80. doi:10.1054/bjoc.2001.2181
78. Faure Vigny H, Heddi A, Giraud S, Chautard D, Stepien G. Expression of oxidative phosphorylation genes in renal tumors and tumoral cell lines. Mol Carcinog (1996) 16:165-72. doi:10.1002/(SICI)1098-2744(199607)16:3165::AID-MC73.0.CO;2-G
79. Chiara F, Castellaro D, Marin O, Petronilli V, Brusilow WS, Juhaszova M, et al. Hexokinase II detachment from mitochondria triggers apoptosis through the permeability transition pore independent of voltage-dependent anion channels. PLoS One (2008) 3:e1852. doi:10.1371/journal.pone.0001852
80. Beutner G, Rück A, Riede B, Welte W, Brdiczka D. Complexes between kinases, mitochondrial porin and adenylate translocator in rat brain resemble the permeability transition pore. FEBS Lett (1996) 396:189-95. doi:10.1016/0014-5793(96)01092-7
81. Shinohara Y, Shima A, Kamida M, Terada H. Uncoupling protein is expressed in liver mitochondria of cold-exposed and newborn rats. FEBS Lett (1991) 293:173-4. doi:10.1016/0014-5793(91)81179-C
82. Rempel A, Mathupala SP, Griffin CA, Hawkins AL, Pedersen PL. Glucose catabolism in cancer cells: amplification of the gene encoding type II hexokinase. Cancer Res (1996) 56:2468-71.
83. Azoulay-Zohar H, Israelson A, Abu-Hamad S, Shoshan-Barmatz V. In self-defence: hexokinase promotes voltage-dependent anion channel closure and prevents mitochondria-mediated apoptotic cell death. Biochem J (2004) 377:347-55. doi:10.1042/BJ20031465
84. Gudnason V, Ingvarsson S, Jonasdottir A, Andresdottir V, Egilsson V. Isoenzyme pattern and subcellular localization of hexokinases in human breast cancer and nonpathological breast tissue. Int J Cancer (1984) 34:63-6. doi:10.1002/ijc.2910340111
85. Yip KW, Reed JC. Bcl-2 family proteins and cancer. Oncogene (2008) 27:6398-406. doi:10.1038/onc.2008.307
86. Nikoletopoulou V, Markaki M, Palikaras K, Tavernarakis N. Crosstalk between apoptosis, necrosis and autophagy. Biochim Biophys Acta (2013) 1833:3448-59. doi:10.1016/j.bbamcr.2013.06.001
87. Quinn BA, Dash R, Azab B, Sarkar S, Das SK, Kumar S, et al. Targeting Mcl-1 for the therapy of cancer. Expert Opin Investig Drugs (2011) 20:1397-411. doi:10.1517/13543784.2011.609167
88. Arbel N, Ben-Hail D, Shoshan-Barmatz V. Mediation of the antiapoptotic activity of Bcl-xL protein upon interaction with VDAC1 protein. J Biol Chem (2012) 287:23152-61. doi:10.1074/jbc. M112.345918
89. Alavian KN, Li H, Collis L, Bonanni L, Zeng L, Sacchetti S, et al. Bcl-xL regulates metabolic efficiency of neurons through interaction with the mitochondrial F1FO ATP synthase. Nat Cell Biol (2011) 13:1224-33. doi:10.1038/ncb2330
90. Thomas RL, Roberts DJ, Kubli DA, Lee Y, Quinsay MN, Owens JB, et al. Gustafsson ÅB. Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure. Genes Dev (2013) 27:1365-77. doi:10.1101/gad.215871.113
91. Brenner C, Cadiou H, Vieira HL, Zamzami N, Marzo I, Xie Z, et al. Bcl-2 and Bax regulate the channel activity of the mitochondrial adenine nucleotide translocator. Oncogene (2000) 19:329-36. doi:10.1038/sj.onc.1203298
92. Rampino N. Somatic Frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science (1997) 275:967-9. doi:10.1126/science.275.5302.967
93. Ionov Y, Yamamoto H, Krajewski S, Reed JC, Perucho M. Mutational inactivation of the proapoptotic gene BAX confers selective advantage during tumor clonal evolution. Proc Natl Acad Sci U S A (2000) 97:10872-7. doi:10.1073/pnas.190210897
94. Li B, Dou QP. Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. Proc Natl Acad Sci U S A (2000) 97:3850-5. doi:10.1073/pnas.070047997
95. Kondo S, Shinomura Y, Miyazaki Y, Kiyohara T, Tsutsui S, Kitamura S, et al. Mutations of the bak gene in human gastric and colorectal cancers. Cancer Res (2000) 60:4328-30. Available from: http://cancerres.aacrjournals.org/content/60/16/4328.long
96. Graber HU, Friess H, Zimmermann A, Korc M, Adler G, Schmid R, et al. Bak expression and cell death occur in peritumorous tissue but not in pancreatic cancer cells. J Gastrointest Surg (1999) 3:74-80. doi:10.1016/S1091-255X(99)80012-2
97. Kang BH, Plescia J, Dohi T, Rosa J, Doxsey SJ, Altieri DC. Regulation of tumor cell mitochondrial homeostasis by an organelle-specific Hsp90 chaperone network. Cell (2007) 131:257-70. doi:10.1016/j.cell.2007.08.028
98. Ghosh JC, Siegelin MD, Dohi T, Altieri DC. Heat shock protein 60 regulation of the mitochondrial permeability transition pore in tumor cells. Cancer Res (2010) 70:8988-93. doi:10.1158/0008-5472.CAN-10-2225
99. Ghosh JC, Dohi T, Kang BH, Altieri DC. Hsp60 regulation of tumor cell apoptosis. J Biol Chem (2008) 283:5188-94. doi:10.1074/jbc. M705904200
100. Sinha D, D'Silva P. Chaperoning mitochondrial permeability transition: regulation of transition pore complex by a J-protein, DnaJC15. Cell Death Dis (2014) 5:e1101. doi:10.1038/cddis.2014.72
101. Rappa F, Farina F, Zummo G, David S, Campanella C, Carini F, et al. HSP-molecular chaperones in cancer biogenesis and tumor therapy: an overview. Anticancer Res (2012) 32:5139-50. Available from: http://ar.iiarjournals.org/content/32/12/5139.long
102. Kang BH, Altieri DC. Compartmentalized cancer drug discovery targeting mitochondrial Hsp90 chaperones. Oncogene (2009) 28:3681-8. doi:10.1038/onc.2009.227
103. Marchi S, Rimessi A, Giorgi C, Baldini C, Ferroni L, Rizzuto R, et al. Akt kinase reducing endoplasmic reticulum Ca2+ release protects cells from Ca2+-dependent apoptotic stimuli. Biochem Biophys Res Commun (2008) 375:501-5. doi:10.1016/j.bbrc.2008.07.153
104. Slomovitz BM, Coleman RL. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Clin Cancer Res (2012) 18:5856-64. doi:10.1158/1078-0432.CCR-12-0662
105. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, González-Barón M. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev (2004) 30:193-204. doi:10.1016/j.ctrv.2003.07.007
106. Wolin EM. PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors. Cancer Lett (2013) 335:1-8. doi:10.1016/j.canlet.2013.02.016
107. Juhaszova M, Zorov DB, Kim S-H, Pepe S, Fu Q, Fishbein KW, et al. Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest (2004) 113:1535-49. doi:10.1172/JCI200419906
108. Luo J. Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy. Cancer Lett (2009) 273:194-200. doi:10.1016/j.canlet.2008.05.045
109. Rasola A, Sciacovelli M, Chiara F, Pantic B, Brusilow WS, Bernardi P. Activation of mitochondrial ERK protects cancer cells from death through inhibition of the permeability transition. Proc Natl Acad Sci U S A (2010) 107:726-31. doi:10.1073/pnas.0912742107
110. Baines CP, Song C-X, Zheng Y-T, Wang G-W, Zhang J, Wang O-L, et al. Protein kinase cepsilon interacts with and inhibits the permeability transition pore in cardiac mitochondria. Circ Res (2003) 92:873-80. doi:10.1161/01.RES.0000069215.36389.8D
111. Yamamura K, Steenbergen C, Murphy E. Protein kinase C and preconditioning: role of the sarcoplasmic reticulum. Am J Physiol Heart Circ Physiol (2005) 289:H2484-90. doi:10.1152/ajpheart.00590.2005
112. Kim JE, He Q, Chen Y, Shi C, Yu K. mTOR-targeted therapy: differential perturbation to mitochondrial membrane potential and permeability transition pore plays a role in therapeutic response. Biochem Biophys Res Commun (2014) 447:184-91. doi:10.1016/j.bbrc.2014.03.124
113. Chiara F, Rasola A. GSK-3 and mitochondria in cancer cells. Front Oncol (2013) 3:16. doi:10.3389/fonc.2013.00016
114. Crompton M. The mitochondrial permeability transition pore and its role in cell death. Biochem J (1999) 341(Pt 2):233-49. doi:10.1042/0264-6021:3410233
115. Halestrap AP, Connern CP, Griffiths EJ, Kerr PM. Cyclosporin A binding to mitochondrial cyclophilin inhibits the permeability transition pore and protects hearts from ischaemia/reperfusion injury. Mol Cell Biochem (1997) 174:167-72. doi:10.1023/A:1006879618176
116. Li J, Ma X, Yu W, Lou Z, Mu D, Wang Y, et al. Reperfusion promotes mitochondrial dysfunction following focal cerebral ischemia in rats. PLoS One (2012) 7:e46498. doi:10.1371/journal.pone.0046498
117. Toffoli S, Michiels C. Intermittent hypoxia is a key regulator of cancer cell and endothelial cell interplay in tumours. FEBS J (2008) 275:2991-3002. doi:10.1111/j.1742-4658.2008.06454.x
118. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol (1927) 8:519-30. doi:10.1085/jgp.8.6.519
119. Boland ML, Chourasia AH, Macleod KF. Mitochondrial dysfunction in cancer. Front Oncol (2013) 3:292. doi:10.3389/fonc.2013.00292
120. Weinhouse S. The Warburg hypothesis fifty years later. Z Krebsforsch Klin Onkol Cancer Res Clin Oncol (1976) 87:115-26. doi:10.1007/BF00284370
121. Ferreira LMR. Cancer metabolism?: the Warburg effect today. Exp Mol Pathol (2010) 89:372-80. doi:10.1016/j.yexmp.2010.08.006
122. Gogvadze V, Orrenius S, Zhivotovsky B. Mitochondria in cancer cells: what is so special about them? Trends Cell Biol (2008) 18:165-73. doi:10.1016/j.tcb.2008.01.006
123. Gwak G-Y, Yoon J-H, Kim KM, Lee H-S, Chung JW, Gores GJ. Hypoxia stimulates proliferation of human hepatoma cells through the induction of hexokinase II expression. J Hepatol (2005) 42:358-64. doi:10.1016/j.jhep.2004.11.020
124. Beutner G, Rück A, Riede B, Brdiczka D. Complexes between porin, hexokinase, mitochondrial creatine kinase and adenylate translocator display properties of the permeability transition pore. Implication for regulation of permeability transition by the kinases. Biochim Biophys Acta (1998) 1368:7-18. doi:10.1016/S0005-2736(97)00175-2
125. Calabrese C, Iommarini L, Kurelac I, Calvaruso MA, Capristo M, Lollini P-L, et al. Respiratory complex I is essential to induce a Warburg profile in mitochondria-defective tumor cells. Cancer Metab (2013) 1:11. doi:10.1186/2049-3002-1-11
126. Santidrian AF, Matsuno-Yagi A, Ritland M, Seo BB, LeBoeuf SE, Gay LJ, et al. Mitochondrial complex I activity and NAD+/NADH balance regulate breast cancer progression. J Clin Invest (2013) 123:1068-81. doi:10.1172/JCI64264
127. He Y, Wu J, Dressman DC, Iacobuzio-Donahue C, Markowitz SD, Velculescu VE, et al. Heteroplasmic mitochondrial DNA mutations in normal and tumour cells. Nature (2010) 464:610-4. doi:10.1038/nature08802
128. Park JS, Sharma LK, Li H, Xiang R, Holstein D, Wu J, et al. A heteroplasmic, not homoplasmic, mitochondrial DNA mutation promotes tumorigenesis via alteration in reactive oxygen species generation and apoptosis. Hum Mol Genet (2009) 18:1578-89. doi:10.1093/hmg/ddp069
129. Chatterjee A, Mambo E, Sidransky D. Mitochondrial DNA mutations in human cancer. Oncogene (2006) 25:4663-74. doi:10.1038/sj.onc.1209604
130. Yokota M, Shitara H, Hashizume O, Ishikawa K, Nakada K, Ishii R, et al. Generation of trans-mitochondrial mito-mice by the introduction of a pathogenic G13997A mtDNA from highly metastatic lung carcinoma cells. FEBS Lett (2010) 584:3943-8. doi:10.1016/j.febslet.2010.07.048
131. Ishikawa K, Takenaga K, Akimoto M, Koshikawa N, Yamaguchi A, Imanishi H, et al. ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science (2008) 320:661-4. doi:10.1126/science.1156906
132. Rimessi A, Bonora M, Marchi S, Patergnani S, Marobbio CMT, Lasorsa FM, et al. Perturbed mitochondrial Ca2+ signals as causes or consequences of mitophagy induction. Autophagy (2013) 9:1677-86. doi:10.4161/auto.24795
133. Gottlieb RA, Carreira RS. Autophagy in health and disease. 5. Mitophagy as a way of life. Am J Physiol Cell Physiol (2010) 299:C203-10. doi:10.1152/ajpcell.00097.2010
134. Elmore SP, Qian T, Trost LC, Nishimura Y, Herman B, Lemasters JJ. Detection of mitochondrial depolarization during autophagy by confocal fluorescence resonance energy transfer (CFRET). Cell Vis J Anal Morphol (1997) 4:170-1.
135. Kang MR, Kim MS, Oh JE, Kim YR, Song SY, Kim SS, et al. Frameshift mutations of autophagy-related genes ATG2B, ATG5, ATG9B and ATG12 in gastric and colorectal cancers with microsatellite instability. J Pathol (2009) 217:702-6. doi:10.1002/path.2509
136. Aita VM, Liang XH, Murty VV, Pincus DL, Yu W, Cayanis E, et al. Cloning and genomic organization of beclin 1, a candidate tumor suppressor gene on chromosome 17q21. Genomics (1999) 59:59-65. doi:10.1006/geno.1999.5851
137. Kim MS, Jeong EG, Ahn CH, Kim SS, Lee SH, Yoo NJ. Frameshift mutation of UVRAG, an autophagy-related gene, in gastric carcinomas with microsatellite instability. Hum Pathol (2008) 39:1059-63. doi:10.1016/j.humpath.2007.11.013
138. Ralph SJ, Rodríguez-Enríquez S, Neuzil J, Saavedra E, Moreno-Sánchez R. The causes of cancer revisited: "mitochondrial malignancy" and ROS-induced oncogenic transformation - why mitochondria are targets for cancer therapy. Mol Aspects Med (2010) 31:145-70. doi:10.1016/j.mam.2010.02.008
139. Galluzzi L, Morselli E, Kepp O, Vitale I, Rigoni A, Vacchelli E, et al. Mitochondrial gateways to cancer. Mol Aspects Med (2010) 31:1-20. doi:10.1016/j.mam.2009.08.002
140. Chatterjee A, Dasgupta S, Sidransky D. Mitochondrial subversion in cancer. Cancer Prev Res (Phila) (2011) 4:638-54. doi:10.1158/1940-6207.CAPR-10-0326
141. Grandemange S, Herzig S, Martinou J-C. Mitochondrial dynamics and cancer. Semin Cancer Biol (2009) 19:50-6. doi:10.1016/j.semcancer.2008.12.001
142. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature (2007) 445:106-10. doi:10.1038/nature05372
143. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 100:3983-8. doi:10.1073/pnas.0530291100
144. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CHM, Jones DL, et al. Cancer stem cells - perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res (2006) 66:9339-44. doi:10.1158/0008-5472.CAN-06-3126
145. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature (2004) 432:396-401. doi:10.1038/nature03128
146. Vega-Naredo I, Loureiro R, Mesquita KA, Barbosa IA, Tavares LC, Branco AF, et al. Mitochondrial metabolism directs stemness and differentiation in P19 embryonal carcinoma stem cells. Cell Death Differ (2014) 21(10):1560-74. doi:10.1038/cdd.2014.66
147. Gogvadze V. Targeting mitochondria in fighting cancer. Curr Pharm Des (2011) 17:4034-46. doi:10.2174/138161211798764933
148. Suh DH, Kim M-K, Kim HS, Chung HH, Song YS. Mitochondrial permeability transition pore as a selective target for anti-cancer therapy. Front Oncol (2013) 3:41. doi:10.3389/fonc.2013.00041